2013—2016年河南省人民医院住院患者口服降糖药应用分析

摘要

目的:了解河南省人民医院(以下简称"我院")住院患者口服降糖药(oral hypoglycemic agents,OHA)的临床应用情况及发展趋势.方法:采用回顾性分析方法,对2013—2016年我院住院患者OHA的应用品种、销售金额、用药频度及限定日费用等进行统计分析.结果:2013—2016年我院住院患者OHA的销售金额分别为51.32、55.37、59.95、67.82万元,呈平稳增长趋势,2014、2015、2016年住院患者OHA的销售金额分别较上一年增长了7.89%、8.28%和13.12%,年均增长率为9.74%;2013—2016年我院住院患者OHA的DDDs分别为105187、116529、128007、145199,亦呈增长趋势,2014、2015、2016年住院患者OHA的DDDs分别较上一年增长了10.78%、9.85%和13.43%.4年来,DDDs排序均居前3位的口服降糖药为阿卡波糖、二甲双胍、格列齐特;二肽基肽酶-4抑制剂前景乐观,其销售金额年增长率居各类OHA之首;胰岛素增敏剂和非磺酰脲类促胰岛素分泌剂的市场份额显著下降.结论:我院住院患者OHA的应用情况基本合理.2型糖尿病患者需要长期甚至终身服用抗糖尿病药,因此,更加安全、有效、经济地使用OHA,使患者获益最大化,仍是值得每个临床工作者进一步深入研究的课题.%OBJECTIVE:To investigate the clinical application status and tendency of oral hypoglycemic agents (OHA) in Henan People's Hospital(hereinafter referred to as "our hospital").METHODS: Statistical analysis was conducted on the application data of OHA during 2013-2016 in terms of categories , consumption sum , defined daily dose system ( DDDs) and defined daily cost ( DDC) , etc.RESULTS:The consumption sum of OHA during 2013-2016 were respectively 513.2, 553.7, 599.5 and 678.2 thousand yuan , the consumption sum of inpatients with OHA were in an increasing tendency and respectively increased by 7.89%, 8.28%and 13.12%during 2013-2016, the annual increasing rate was 9.74%.The DDDs of inpatients with OHA were respectively 105187, 116529, 128007 and 145199, which also were in an increasing tendency and respectively increased by 10.78%, 9.85%and 13.43%.Four four years , the top three OHA ranked by DDDs were respectively acarbose , metformin and gliclazide .The DPP-4 inhibitor had a promising future , its increasing rate of consumption sum took the lead of the consumption sum of OHA . Yet the market share of insulin agonist and sulfonylurea insulinotropic agents decreasing significantly .CONCLUSIONS:The application of OHA in our hospital is basically rational .Patients with type-2 diabetes mellitus need to take OHA for a long time even life-long.Therefore, safe, effective and economical application of OHA and maximization of patients ' benefits are still an essential task for the clinical staff to conduct the further research .